Biotech Growth Slows As Cost Containment Hits Home
Executive Summary
EY Lifesciences annual report into the biotech industry released in time for BIO finds a shift in capital flows as funds from China and the UK began to make their mark. Cost containment hit revenue growth and net income declined, while industry was told to embrace new technologies to thrive long term.